OptiBiotix Health Plc subsidiary receives USFDA letter confirming LPLDL®’s GRAS status

  • OptiBiotix Health Plc’s (OPTI) fully-owned subsidiary ProBiotix Health Ltd has finalized the process validation under Pharmaceutical GMP (Good Manufacturing Practices) for LPLDL® as a drug substance.
  • The company has also received a letter from the USFDA (United States Food and Drug Administration) confirming LPLDL®s GRAS status (Generally Recognized As Safe status), a designation that a substance added to food is considered safe.
  • On 9th October 2019, at the time of writing, GMT 08:08 AM, OPTI shares were trading at GBX 47.00, up by 3.25 points or 7.43% against the previous day closing price.